Shopping Cart
- Remove All
- Your shopping cart is currently empty
BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor that blocks the formation of Neutrophil Extracellular Traps and delays the progression of multiple myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays symptom onset and disease progression. Targeting PAD4 may be beneficial for treating multiple myeloma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $82 | In Stock | |
10 mg | $145 | In Stock | |
25 mg | $297 | In Stock | |
50 mg | $533 | In Stock | |
100 mg | $759 | In Stock | |
1 mL x 10 mM (in DMSO) | $85 | In Stock |
Description | BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor that blocks the formation of Neutrophil Extracellular Traps and delays the progression of multiple myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays symptom onset and disease progression. Targeting PAD4 may be beneficial for treating multiple myeloma. |
In vivo | Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression. |
Molecular Weight | 472.58 |
Formula | C27H32N6O2 |
Cas No. | 1550371-22-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 10 mg/mL (21.16 mM) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.